Clinical Trial Search

Primary: Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. — 13; 41 Participants

Primary: Number of Index Patients Eradicated of S. Aureus Carriage - 1 Month After Performing Decolonization Measures — 39; 35 Participants — p=1.00

Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score

Primary: Assessment of Safety Through Clinical Examinations, Clinical Laboratory Results, Self-reported Diary Reactogenicity Data and Adverse Event Reports — 37; 40; 28; 36 events

Primary: Carrier Rate for Staphylococcus Aureus — 20.8 percentage of subjects

Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035

Primary: Number of Subjects With Single Negative Polymerase Chain Reaction (PCR) Result and 3 Negative Culture Assays — 96.6 percentage of participants

Primary: Apparent Eradication of Nasal Carriage of SA — 9 participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) Following Multiple Doses of Intravenous AP-Sa02. — 17; 10; 6; 2 number of…

Primary: Medically Attended Skin and Soft Tissue Infections (MA-SSI) — 20.9; 17 percentage of partipants

Primary: Re-infection With S. Aureus — 10; 11; 0; 0 participants with S. aureus re-infection — p=0.356

Primary: Change in the Abundance of Staphylococcus Aureus in the Nose After Decolonization — -781 fg/uL

Primary: Recurrence of Cutaneous Abscess — 5; 7 Participants

Primary: Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit — 132; 136; 57; 62 Participants

Primary: Number of Participants Who Experienced Dose-limiting Toxicities — 0; 0; 0; 0 participants

Primary: Plasma Retapumulin Pharmacokinetic Parameters by Treatment at Days 1 and 3 Evaluated by Plasma AUC After Dosing — 0.8663; 0.3816; 4.2802; 2.0881 ng.h /mL

Primary: Apparent Eradication of Nasal SA After the Last Dose of XF-73 Based on Semi-quantitative SA Scores From a Broth Enrichment Method. — 3; 1; 4 participants — p=0.792

Primary: Efficacy Endpoint: All-Cause Mortality by Day 28 — 1; 2; 2; 0 Participants

Primary: Treatment-associated Change in S. Aureus Colonization During a Typical 10-hour Work Day — -99.8; -13.5 Percent change in colonization — p=<0.01

Primary: Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol Population — 457; 487; 182; 187 participants

Primary: The Presence of MRSA on Repeated Swabs to Assess the Efficacy of These Medications on Clearing MRSA Colonization — 12; 14; 0 Participants

Primary: Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP Population — 95; 81; 70; 93 Participants…

Primary: Relative Staphylococcus Aureus Abundance — 0.13; 12.2 ratio to baseline S. aureus abundance

Primary: Number of Participants With Eradiction of S. Aureus From the Oropharyngeal at 7 Days — 18; 7 Participants

Primary: Number of Participants With Recurrent Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization — 2; 3 Participants

Primary: Number of Participants With Antibiotic Usage at the Time of the ED Visit — 97; 96 Participants

Primary: Number of Participants Eradicated of S. Aureus Carriage - 1 Month After Intervention — 24; 35; 35; 34 Participants

Primary: Recurrent Infection — 1; 3; 1 participants

Primary: MRSA Transmission — 0.20; 0.02; 0.11; 0.01 Proportion of swabs positive for MRSA

Primary: Number of Participants With Solicited Adverse Events (AEs) During Days 1-7 — 2; 1; 17; 4 participants